Contracts › 75N91025C00051
75N91025C00051: Sbir Phase Ii - Enhanced Overall Survival in High-Risk Pediatric Solid Tumors Using a Novel Oral Small Molecule
Awarded to Novomedix Llc by National Institutes of Health (NIH).
$3.0Mobligated
$3.0Mpotential value
14 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91025C00051 |
|---|---|
| Awardee | Novomedix Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 16 |
| Period of performance | 15 September 2025 to 14 September 2027 |
| Potential end | 14 September 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record